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purposE  
Retrospectively evaluate concurrent psychotropic medications in 
schizophrenic patients prior to- and during long-acting injectable (LAI) 
antipsychotic therapy
background
  Approximately one percent (1%) of the adult population (2.4 million) has 
schizophrenia1  
  Schizophrenic patients oftentimes have multiple comorbid mental and 
substance-abuse issues, and other health-related comorbidities2
  Medication compliance is of immense importance in these patients2,3,4  
– Non-adherence or partial medication compliance occurs in >50% of     
   schizophrenic patients5
  Primary goals of therapy: minimize or eliminate the symptoms of 
schizophrenia, maximize the patients’ quality of life and social functioning, 
maintain a level of mental stability6
  Meta-analysis reviewed 613 outpatient ‘mirror-image’ studies7 
– Assessed evidence of efficacy for oral versus LAI antipsychotic medications7    
– Hospitalization days for patients taking LAI antipsychotic medications versus  
   oral preparations: 17,860 versus 75,492 days7  
– Relapse rates for patients using LAI antipsychotics compared to oral  
   preparations: 30% versus 47.1% patients, statistically significant7
  Olfson et al. found that patients receiving LAI preparations compared 
with oral antipsychotics continued to require multiple concurrent oral 
psychotropics8 
– Antidepressants, anxiolytics/hypnotics, mood stabilizers, and oral antipsychotics8
  Shi et al. evaluated characteristics of patients taking LAI antipsychotics 
versus oral antipsychotics9  
– Two-thirds of LAI antipsychotic group concurrently received more psychotropic  
   medications compared to those on oral antipsychotics only9 
– LAI antipsychotic group tended to be more difficult-to-treat, non-compliant and 
   refractory to traditional oral antipsychotics9
  If LAI antipsychotics can decrease the number of concurrent 
psychotropic medications, this may increase patient compliance
  No trials directly assess the number of concurrent psychotropic 
medications prior to- and during LAI antipsychotic therapy
study dEsign
  Retrospective chart review
  Inclusion criteria: 
– Patients prescribed LAI antipsychotic (fluphenazine decanoate, haloperidol  
   decanoate, paliperidone palmitate, and long-acting risperidone) for a minimum  
   period of 180 days for schizophrenia 
– Patients who received LAI antipsychotic between January 2004 and July 2010
  The primary outcome of the study will be the number of concurrent 
psychotropic medications prior to LAI antipsychotic therapy, and during 
LAI antipsychotic treatment
  The secondary outcome will be patient relapse rates prior to LAI 
antipsychotic therapy, and during LAI antipsychotic treatment
mEthods
  Chart review evaluating number of concurrent psychotropic medications and 
relapse rates prior to- and during LAI antipsychotic treatment 
– Number of concurrent psychotropic medications will be tallied for 180 days prior to-  
   and 180 days during LAI antipsychotic treatment 
– Relapse rate will be examined, as indicated by number of emergency room visits,  
   hospitalizations and admissions for a schizophrenic episode 
– Psychotropic medications: any medication used to treat symptoms of a mental disorder, 
   including schizophrenia, depression, bipolar disorder, anxiety disorders, and attention  
   deficit-hyperactivity disorder (ADHD)
  Other patient data to be collected includes: 
– Age, gender, weight, renal function 
– Patient comorbidities, age and date of schizophrenia diagnosis, previously documented  
   failed medications 
– Dates and durations of admissions for schizophrenia exacerbations 
– Patient Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) information  
   for diagnosis, Positive and Negative Syndrome Scale (PANSS) symptoms 
– Factors that may have contributed to acute episodes or mental/mood status changes   
   (including acute illness, trauma, illicit drug use)
  Following data collection, the number of concurrent psychotropic medications 
and relapse rates will be compared
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